Questions and Answers
What is the pharmacologic classification for Carbidopa-Levodopa?
Dopamine Agonist
What is indicated for the use of Carbidopa-Levodopa?
Parkinson's Disease
What are the therapeutic goals/actions for Carbidopa-Levodopa? (Select all that apply)
What is converted into dopamine?
Signup and view all the answers
What is an inhibitor that prevents the breakdown of dopamine?
Signup and view all the answers
Carbidopa crosses the blood-brain barrier (BBB).
Signup and view all the answers
Which conditions are contraindicated for Carbidopa-Levodopa? (Select all that apply)
Signup and view all the answers
What are some adverse effects of Carbidopa-Levodopa? (Select all that apply)
Signup and view all the answers
Which medications interact with Carbidopa-Levodopa? (Select all that apply)
Signup and view all the answers
What does the 'wearing off' effect refer to?
Signup and view all the answers
What are some patient education points regarding Carbidopa-Levodopa?
Signup and view all the answers
What are the desired outcomes for patients taking Carbidopa-Levodopa?
Signup and view all the answers
Study Notes
Pharmacologic Classification
- Carbidopa-Levodopa is classified as a dopamine agonist.
Indications
- Primarily indicated for the treatment of Parkinson's Disease.
Therapeutic Goals and Actions
- Aims to provide relief from tremors and rigidity in patients with Parkinson's Disease.
- Levodopa is converted into dopamine in the brain to enhance motor function.
- Carbidopa inhibits the enzyme that breaks down dopamine, increasing its availability in the brain.
Key Components
- Levodopa is the substance that gets converted into dopamine.
- Carbidopa prevents the breakdown of dopamine, enhancing the effectiveness of Levodopa.
Pharmacokinetics
- Carbidopa does not cross the blood-brain barrier but can cross the placenta.
- Both Carbidopa and Levodopa are excreted in breast milk.
Contraindications
- Not recommended for patients with glaucoma.
- Caution advised for individuals with melanoma.
Adverse Effects
- Potential side effects include dyskinesia, nausea, and vomiting.
- Can lead to melanoma, darkened sweat and urine, cardiac dysrhythmias, hypotension, and muscle cramps.
Drug Interactions
- Non-selective MAOIs can interact negatively with Carbidopa-Levodopa.
- Interactions with benzodiazepines, antipsychotics, and vitamin B6 (Pyridoxine) can occur.
- Dietary protein may impair the effectiveness of Levodopa.
- Anticholinergics may work in conjunction with cholinergic medications.
Nurse Safety Considerations
- "Wearing off" phenomenon may occur, where the medication loses effectiveness over time (5-10 years).
- "Wearing on/off" phenomenon affects some patients, fluctuating between symptom control and lack of control.
Patient Education
- Advise against a high-protein diet, which can impair Levodopa absorption.
- Monitor for indications of melanoma risk.
- Educate patients that vitamin B6 can interfere with Levodopa's effectiveness.
- Discuss the "wearing off" effect and its potential impact on treatment.
Outcomes
- Expected to see resolutions of Parkinson's Disease signs and symptoms.
- Therapeutic effects can take anywhere from 2-3 weeks to 6 months to manifest fully.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
Test your knowledge on Carbidopa-Levodopa, its pharmacologic classification, indications for use in Parkinson's Disease, and its therapeutic goals. This quiz will help reinforce your understanding of this essential anti-Parkinson's medication.
